Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin

Novo Nordisk A/S3,809 enrolled

Overview

The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes. Full acronym for this study: COMMIT - CLEAN SWITCH

Study Type

OBSERVATIONAL

Enrollment

3,809

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

biphasic insulin aspart 30DRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

insulin detemirDRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with type 2 diabetes * Patients treated with human soluble insulin, NPH insulin or premixed human insulin * Patients willing to sign informed consent * Selection of study participants at the discretion of the physician Exclusion Criteria: * Subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30 * Subjects who were previously enrolled in this study * Subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients

Locations (1)

Novo Nordisk Investigational Site

Bratislava, Slovakia

Outcomes

Primary Outcomes

Metabolic control measured as HbA1c

Time frame: for the duration of the study